

الاهمية الاكلينيكية لذائب CD4v6 في مرضى سرطان القولون والمستقيم

رساله

توطئه للحصول على درجة الماجستير
في الباثولوجيا الاكلينيكية والكيميائية

مقدمه من

طبيبه / شيماء جمال حسن بيومي
بكالوريوس الطب والجراحة العامة
كلية الطب- جامعة عين شمس

تحت إشراف

الأستاذ الدكتور / سوسن سعيد حافظ
أستاذ الباثولوجيا الإكلينيكية والكيميائية
كلية الطب- جامعة عين شمس

الأستاذ الدكتور / كريم يحيى علي شاهين
أستاذ الباثولوجيا الإكلينيكية والكيميائية
كلية الطب- جامعة عين شمس

الدكتور / رانيا صلاح الدين شاهين
مدرس الباثولوجيا الإكلينيكية والكيميائية
كلية الطب- جامعة عين شمس

كلية الطب
جامعة عين شمس

٢٠١١

CLINICAL SIGNIFICANCE OF SOLUBLE CD44V6 IN PATIENTS WITH COLORECTAL CANCER

Thesis

Submitted for Partial Fulfillment of Master Degree
In **Clinical and Chemical Pathology**

By

Shaimaa Gamal Hassan Baiomy

(M.B, B.Ch)

Ain Shams University

Supervised by

Professor/ Sawsan Said Hafez

Professor of Clinical and Chemical Pathology

Faculty of Medicine -Ain Shams University

Professor/ Karim Yehia Aly Shaheen

Professor of Clinical and Chemical Pathology

Faculty of Medicine -Ain Shams University

Doctor/ Rania Salah El-Din Shahin

Lecturer of Clinical and Chemical Pathology

Faculty of Medicine -Ain Shams University

Faculty of Medicine
Ain Shams University
2011

SUMMARY

Colorectal cancers, among other neoplasms are in the third place in morbidity and mortality after the breast and lung cancers in women and prostate and lung cancers in men. Colorectal cancer is also the third cause of death among all neoplasma diseases.

The incidence of this disease has been rising especially in developed countries. The survival rate after radical operative treatment and chemo- or radiotherapy is still unsatisfactory. The 5-year survival after radical treatment was about 60% in the United States and Western Europe, whereas it was only about 40% in Eastern Europe. The recurrence of the disease is dependent on the progression of neoplasma metastases to lymph nodes and distal organs and is the most common cause of death.

The routine examinations of specimens with the estimation of the histopathological grade of malignancy, clinical evaluation and even the changes in CEA, CA19.9 levels in the serum evaluation all still have limited ability and require serial measurements to identify patients with colorectal cancer.

Therefore, there is a desperate need for an early and sensitive marker for detection of colorectal cancer in order to interfere early and thus improve the prognosis. A candidate marker for detection of colorectal cancer is CD44.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ
تَكُنْ تَعْلَمُ وَكَانَ
فَضْلُ اللَّهِ عَلَيْكَ
عَظِيمًا

صدق الله العظيم
سورة النساء آية
(١١٣)



Acknowledgment

Thanks are given to **ALLAH** the source of all knowledge, for guiding me through and giving me the strength to complete this study the way it is.

It has been a great honor to proceed this work under the supervision of **Professor/ Sawzan Said Hafez**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain shams University. I am greatly indebted to her for suggesting and planning the subject, supervising the whole work, reading and criticizing the manuscript. I will never forget her unlimited help, continuous support, kind encouragement, constructive criticism and wise guidance. To her words of praise are not sufficient and I am really greatly indebted to her.

I would like also to express my sincere gratitude and appreciation to **Professor/ Karim Yehia Aly Shaheen**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for his helpful guidance, valuable advice, meticulous care, great effort and generous help in this work.

I would like to express my deep obligation to **Doctor/ Rania Salah El-Din Kamel Shahin**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her generous help and support throughout every step in this work.

I would also like to thank **Doctor/ Amal Abdel Sameea**, Lecturer of Oncology, Faculty of Medicine, Ain shams University, for her generous help in collection of cases at Ain Shams University Hospitals.

Last but not least, I express my love to my family for their continuous encouragement and help to me all the time, so I dedicate this work to them.

LIST OF CONTENTS

Title	Page No.
LIST OF TABLES.....	i
LIST OF FIGURES.....	iii
LIST OF ABBREVIATIONS.....	iv
INTRODUCTION AND AIM OF WORK.....	1
REVIEW OF LITERATURE	
I- COLORECTAL CANCER.....	4
A) Epidemiology of Colorectal Cancer.....	4
B) Risk Factors and Etiology of Colorectal Cancer.....	5
C) Pathogenesis of Colorectal Cancer	14
D) Histopathological Types of Colorectal Tumors.....	22
E) Grading and Staging of Colorectal Tumors.....	23
• Staging of colorectal tumors.....	23
• Grading of colorectal tumors	27
F) Clinical Presentation of Colorectal Cancer.....	29
G) Screening of Colorectal Cancer	31
H) Diagnosis of Colorectal Cancer.....	44
• Clinical diagnosis of colorectal cancer.....	44
• Laboratory diagnosis of colorectal cancer.....	46
II- CD44 molecule	88
A) Nomenclature	88
B) Isoforms.....	88
C) Chemistry	90
D) Mode of action	90
E) Genetic Control of CD44 Expression	94

LIST OF CONTENTS (Cont...)

Title	Page No.
F) Functions of CD44	95
G) Clinical Utility of CD44	99
• CD44 in inflammatory and non malignant conditions.....	99
a- Wound healing.....	99
b- Endometrial expression during the human menstrual cycle.....	100
c- Rheumatoid arthritis	100
d- Immune deficiency virus.....	101
• CD44 in malignant disease	102
a- Alimentary tract cancer.....	102
b- Nasopharyngeal carcinoma.	108
c- Lung cancer.....	108
d- Mesotheliomas	109
e- Breast cancer	110
f- Tumors of the nervous system	111
g- Head and neck squamous cell carcinoma.....	112
h- Thyroid carcinoma.....	113
i- Genitourinary tract cancer.	114
j- Gynecological cancer.....	115
k- Melanoma.	116
l- Haematological malignancy.....	116
H) Methods of Determination of CD44 in Tissues and Body Fluids	118
I) Determination of CD44 Gene Expression	123
SUBJECTS AND METHODS	126
RESULTS	151

LIST OF CONTENTS (Cont...)

Title	Page No.
DISCUSSION	168
SUMMARY	175
RECOMMENDATIONS AND CONCLUSION	179
REFERENCES	180
ARABIC SUMMARY	—

LIST OF TABLES

Tab. No.	Title	Page No.
Table (1):	Dukes' Staging System for Colorectal Cancer	24
Table (2):	Modified Astler-Coller Classification of Dukes' Staging System for Colorectal Cancer	25
Table (3):	TNM Classification of Colorectal Cancer	26
Table (4):	Causes of False-positive and Negative Test Result Using The Hemocult Method	34
Table (5):	Advantages and Limitations of Fecal Occult Blood Testing	35
Table (6):	Qualitative Analysis of Screening Options for Colorectal Cancer	43
Table (7):	Advantages and Disadvantages of Colorectal Cancer Screening Tests	44
Table (8):	The Sensitivity of CEA in Patients with Colorectal Cancer, According to Stage	57
Table (9):	Diagram Depicting An Example of The Arrangement of Blanks, Standards and Samples in The Microwell Strips	140
Table (10):	Descriptive Statistics of The Studied Parameters in The Different Studied Groups.....	154
Table (11):	Descriptive Statistics of Sex Distribution in All Studied Groups	155
Table (12):	Descriptive Statistics of The Levels of The Studied Markers in Different Stages of Lymph Node Metastasis in Group II	156
Table (13):	Descriptive Statistics of The CD44v6 Levels in Presence and Absence of Organ Metastasis	157

LIST OF TABLES (Cont...)

Tab. No.	Title	Page No.
Table (14):	Descriptive Statistics of The CD44v6 Levels in Dukes' Stages C and D	157
Table (15):	Statistical Comparison Between The Studied Markers in All Studied Groups Using Kruskall Wallis Test.....	158
Table (16):	Statistical Comparison Between Group I and Group III As Regards The Studied Markers Using Wilcoxon's Rank Sum Test.....	158
Table (17):	Statistical Comparison Between Group II and Group III As Regards The Studied Markers Using Wilcoxon's Rank Sum Test.....	159
Table (18):	Statistical Comparison Between Group I and Group II As Regards The Studied Markers Using Wilcoxon's Rank Sum Test.....	160
Table (19):	Correlation Between CD44v6 Levels and Various Studied Parameters in All Studied Groups Using Spearman's Rank Correlation Coefficient (rs) Test.....	161
Table (20):	Comparison Between The Level of Tumor Markers in Different Stages of Lymph Node Metastasis (N0, N1 and N2) in Group II Using Kruskall Wallis Test.....	162
Table (21):	Statistical Comparison of CD44v6 Levels in Different Grades of Tumor Invasion Using Kruskall Wallis Test.....	163
Table (22):	Statistical Comparison of CD44v6 Levels According to Organ Metastasis Using Wilcoxon's Rank Sum Test.....	164
Table (23):	Statistical Comparison of CD44v6 Levels in Dukes' Stages C and D Within Group II Using Wilcoxon's Rank Sum Test	165
Table (24):	The Diagnostic Performance of CD44v6 for Discriminating Patients from Control	166

LIST OF FIGURES

Fig. No.	Title	Page No.
Figure (1):	Well-differentiated Adenocarcinoma	27
Figure (2):	Moderately Differentiated Adenocarcinoma	28
Figure (3):	Less Differentiated Adenocarcinoma with Muscular Tunic Invasion	29
Figure (4):	The Epidermal Growth Factor Receptor Signaling	60
Figure (5):	Human CD44 Structure.	89
Figure (6):	A Single CD44+ Colorectal Cancer Cell Could Initiate A Tumor.	93
Figure (7):	Schematic Representation of The Coding Region of The Human CD44 Gene	125
Figure (8):	Diagram Showing The Principle of CEA Assay by ECLIA.....	130
Figure (9):	Principal of CD44v6 Assay	135
Figure (10):	Preparation of sCD44var (v6) Standard Dilutions	139
Figure (11):	Representative Standard Curve for sCD44var (v6) ELISA	142
Figure (12):	ROC Curve Analysis Showing The Diagnostic Performance of CD44V6 for Discriminating Patients from Control.....	167

LIST OF ABBREVIATIONS

Abbrev.	Full term
APC	Adenomatous Polyposis Coli
Bcl-2	B-cell Lymphoma 2 Proto-oncogene.
CSCs	Cancer Stem Cells.
CA 19.9	Carbohydrate Antigen 19-9.
CEA	Carcinoembryonic Antigen.
CD44v	CD44 Variant.
CLIA	Chemiluminescence Immunoassay.
CD44	Cluster of Differentiation 44.
CV	Coefficient of Variation.
CCSA	Colon Cancer-specific Antigen.
CRC	Colorectal Carcinoma.
CT	Computed Tomography.
CI	Confidence Interval.
DNA	Deoxyribonucleic Acid
DK	Dermokine.
ELISA	Enzyme-linked Immunosorbent Assay.
EGFR	Epidermal Growth Factor Receptor.
CD44e	Epithelial CD44.
ECM	Extracellular Matrix.
FAP	Familial Adenomatous Polyposis.
FOBT	Fecal Occult Blood Test.
CD44H	Hematopoietic CD44.
HNPCC	Hereditary Non Polyposis Colorectal Cancer.
HPLC	High Performance Liquid Chromatography.
HRP	Horseradish Peroxidase.
HEV	Human Endothelial Vessels.
HA	Hyaluronic Acid.
IHC	Immunohistochemistry.

LIST OF ABBREVIATIONS (Cont....)

Abbrev.	Full term
IR	Interquartile Range.
Kb	Kilobase
kDa	Kilo Dalton.
K-Ras	Kirsten Rat Sarcoma Gene.
LLD	Lower Limit of Detection.
\bar{X}	Mean.
mRNA	Messenger RNA.
mAb	Monoclonal Antibody.
BCIP/NBT	5-Bromo-4-Chloro-3-Indolyl Phosphate System/Nitro Blue Tetrazolium.
O.D.	Optical Density.
OPN	Osteopontin.
PBS	Phosphate Buffer Saline.
PLSCR1	Phospholipid Scramblase 1.
p	Probability.
PSGL-1	P-Selectin Glycoprotein Ligand-1.
RIA	Radioimmunoassay.
RTK	Receptor of Tyrosin Kinase.
RT-PCR	Reverse Transcriptase Polymerase Chain Reaction.
SDS-PAGE	Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis.
r_s	Spearman's Rank Correlation Coefficient.
CD44s	Standard CD44.
SD	Standard Deviation.
Σ	Sum of Observed Values.
TBS	Trisbuffered Saline.
TNM	Tumor Node Metastasis.
VEGF	Vascular Endothelial Growth Factor.
Z	Wilcoxon's Rank Sum Test.

INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer worldwide, with an annual incidence of approximately 1 million cases and an annual mortality of more than 500,000 (*Parkin et al., 2005*). It contributes for 8.9% of all cancers in the world, and 6.5% of all cancers in Egypt (*El-Bolkainy et al., 2006*).

Fecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy, digital rectal examination are reliable methods for diagnosis of colorectal cancer (*Adolfo, 2009*).

Although histopathology is the most important tool in the diagnosis of colorectal cancer, tumor markers as CEA and CA19.9 are important as diagnostic markers, prognostic markers and surveillance markers (*Yamashita et al., 2009*).

The American Society for Clinical Oncology recommends that CEA is the only marker of choice for monitoring the response of metastatic disease to systemic therapy at present (*Yamashita et al., 2009*).

On the other hand CA19.9 was evaluated as a prognostic marker for colorectal cancer. Simultaneous use of the two markers is useful in evaluating the therapeutic effect and monitoring the recurrence of advanced colorectal cancer (*Park et al., 2009*).

Short for cluster of differentiation 44(CD44) is an adhesion molecule of the hyaluronan receptor family. It has 10 splice variants take the numbers from 1 to 10. CD44 has in recent years been intensively studied in connection with different forms of cancer, where CD44 may regulate invasiveness and tumor progression. Although major functions involve adhesion and migration, CD44 also affects leukocyte homing, recruitment, phagocytosis, matrix remodeling, proliferation and apoptosis (*Alexandra et al., 2009*).

CD44v6 is the soluble CD44 splice variant containing exon v6. Several studies found it higher in patients with metastasis than in primary patients implying the role of this molecule in tumor progression (*Amirghofran et al., 2008*).